On October 20th 2022 Flanders Vaccine organises its 7th edition of Immunity for Health in Antwerp, Belgium.
This year the theme is “ONE HEALTH: Cross pollination between human and veterinary immune interventions“.
The COVID-19 pandemic has clearly demonstrated how an emerging human infectious disease caused by a zoonotic pathogen can have a huge impact on public health, but also on the society as a whole and on global economies. Once again we have been confronted with the important link between human, animal and environmental health.
At Flanders Vaccine we endorse the “One Health” principle, bridging veterinary and human medicine. With Immunity for Health 2022, we want to encourage and facilitate mutual learning and collaboration between the two sectors to drive vaccine and immunotherapeutic development and improve human and animal health.
We will take a look at successful technologies and advances in veterinary vaccine – and immunotherapy development and identify unique opportunities for applications in the human sector and vice versa. Differences and similarities in regulatory aspects in both sectors will also be addressed.
Flanders Vaccine is honoured to welcome some renowned experts in the field and we are looking forward to be inspired by their talks! Research groups and sme’s will be given the opportunity to share their innovative ideas, technologies or new products with the audience during the pitch sessions.
09:00 | Registration – Coffee & Croissants
09:45 | Welcome by Fran Van Heuverswyn, Flanders Vaccine
10:00 | Opening Keynote: Translating Human Innovations into Veterinary Value
Jarne Elleholm, CEO Stonehaven Incubate
Topic: Learnings from establishing veterinary spin-out companies based on human innovations
VETERINARY VACCINES AND INSIGHTS FOR HUMAN APPLICATIONS – Moderator: Sven Arnouts, Provaxs, Ghent University
10:30 | Development of veterinary vaccines and insights for a one health approach
Topic: The process of developing vaccines for new pathogens or variants, starting from the veterinary field with parallels and suggestions for human vaccines; how human vaccinology could benefit from animal models
11:00 | Coffee break
12:00 | Pitch session
- Third-generation sequencing, the new diagnostic power in the veterinary world offers opportunities for One Health control strategies – Sebastiaan Theuns, Pathosense
- AstriVax , a novel human vaccine platform company addressing challenges in vaccinology – Hanne Callewaert, Astrivax
- Zoonotic surveillance as a prerequisite for vaccination strategies – Sofie De Broe, Sciensano
12:30 | Lunch & Networking break
COMPARATIVE ONCOLOGY APPROACH: IMMUNOTHERAPY FOR CANINE AND HUMAN PATIENTS – Moderator: Laetitia Cicchelero, Ghent University
Federica Cavallo, Full Professor Immunology, University of Turin, Italy
Topic: Introduction to tumor immunology, immunotherapy, and comparative oncology, with the oral melanoma vaccine as a case study
14:25 | Vimentin-targeted immunotherapy: an example of collaboration across species for the development of innovative immunotherapeutics
Arno Roos, Clinical Director Veterinary Referral Centre Korte Akkeren & Head of Oncology, Evidensia, The Netherlands
Topic: Vimentin-targeted immunotherapy trials in veterinary patients is example of how collaborations between the human and veterinary sector can stimulate innovations in immunotherapy
14:50 | Q&A afternoon session
15:00 | Coffee break
15:30 | Pitch session
- Ghent University’s Cross-Health platform: health innovation across species – Laetitia Cicchelero, Ghent University
- VAX-ID® – Unlocking Intradermal Vaccination – Momen Naim Mousa Rbeihat, Idevax
16:00 | Closing keynote: Specific immunotherapy of cancer: translational opportunities and innovations
Topic: Current state of immunotherapeutic strategies in cancer will be reviewed and opportunities for improving efficacy and immunological specificity for human and veterinary patients will be discussed.
16:45 | Closing Word & Pitch Award
17:00 | Networking reception
Pitch your innovative ideas
Scientists and young entrepreneurs are invited to pitch their promising project results or innovative technologies related to one of the two sessions of Immunity for Health 2022.
Please complete the call for abstract template and submit your application. The deadline for application is extended until September 20th 2022.
The scientific committee of Immunity for Health will review all applications and select the pitches to present their project at Immunity for Health in Antwerp, Belgium (only on-site presentations).
On the day of the event, a prize will be awarded for the best pitch.
Pitch Award Sponsored by BIPP
Join the conference as a sponsor or exhibitor!
You can be part of Immunity for Health and have a spot on the exhibitor market for € 1.500 (VAT excluded). Spots are limited!
Enlarge the visibility of your company by applying for one of our Sponsorships.
As a PLATINUM SPONSOR of the conference, you will achieve maximum visibility with an exhibition booth, company logo on all communication channels and 4 free access entry tickets.
Benefits of the sponsorships can be found on the next page. In addition to the standard packages, we can also work with you to customize a sponsorship package tailored to your unique needs and budgets.
Flanders Vaccine members will receive a 15% discount on all our sponsorship packages.
- Flanders Vaccine member: 150 EUR (+ 21% VAT)
- Flanders Vaccine non-member:
- Academic/non-profit: 200 EUR (+ 21% VAT)
- Industry: 300 EUR (+ 21% VAT)
- Students (master/bachelor, PhD students): 50 EUR (+ 21% VAT)
Deadline registration: 11 October 2022
Venue: Park Inn hotel Antwerp Berchem, Borsbeeksebrug 34, 2600, Antwerp, Belgium
Notifications received upon 2 weeks before the start of the event, get refunded for 100%. Cancellation requests received less than 2 weeks before the start of the event won’t be refunded. No-shows on the day of the event will not be refunded and are requested to pay the full fee. Replacement by a colleague is always allowed and should be reported to the organizers.
Flanders Vaccine is supported by GlaxoSmithKline, Sanofi, Janssen Pharmaceuticals, Pfizer and MSD.